AN EPIGENETIC APPROACH

EpicentRx technologies work through the simultaneous modulation of multiple epigenetic targets with tremendous potential to treat multiple disorders including cancer.

 

FROM AEROSPACE TO INNER SPACE

EpicentRx is a Silicon Valley-based discovery and development company that has developed a comprehensive portfolio of proprietary NASA-derived molecules with novel mechanisms of action.

 

IMMUNO- STIMULATION

Immunostimulation induces tumor-infiltrating lymphocytes, excessive cytokine production, and M2 to M1 macrophage polarization.

 

RESETTING THE CANCER CLOCK

RRx-001 has the potential to resensitize tumors to failed chemotherapies, turning back the clock and resetting the cancer timeline.

 

VIMMUNE ™ PLATFORM: ARMED AND TARGETED ONCOLYTIC VIRUSES

EpicentRx has developed a platform called VIMMUNE™ of tumor-targeted replication-competent adenoviruses armed with immunostimulatory transgenes to induce cytotoxic T lymphocyte responses.

 

CYTOKINE PRODUCTION

Emerging research places epigenetic inhibitors like RRx-001 at the intersection between epigenetics and anti-tumor immunity through the activation of a class of proteins called interferons, a type of cytokine, which stimulates the immune system to kill cancer cells.

 

EPI-IMMUNOLOGY

RRx-001 potential sensitization and resensitization to immunotherapy (e.g. anti-PD-1).

 

p53 DEPENDENCE

RRx-001 mediates p53 induction with apoptosis and tumor suppression.

 

IMMUNOGENIC CELL DEATH

RRx-001 and the VIMMUNE oncolytic viruses appear to induce immune dependent tumor cell death or immunogenic cell death (ICD).